Pre-B cell acute lymphoblastic leukemia (ALL) is a relatively common childhood cancer, which has an increased incidence in children with Down syndrome. Although the majority of children with B-ALL survive, they suffer many debilitating side effects from the treatment, and in some cases the disease returns. We are performing experiments to identify new drug targets, such as a protein named DYRK1A, which control the activity and level of other important proteins. In addition, we are testing whether molecules that block the activity of DYRK1A show anti-leukemia activity with the goal of bringing these drugs to clinical trials.
|Effective start/end date||4/1/15 → 6/30/16|
- Rally Foundation, Inc. (AGMT- 4/17/15)
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.